» Articles » PMID: 20306036

Molecular Imaging in Atherosclerosis

Overview
Date 2010 Mar 23
PMID 20306036
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerosis is the major cause of cardiovascular disease, which still has the leading position in morbidity and mortality in the Western world. Many risk factors and pathobiological processes are acting together in the development of atherosclerosis. This leads to different remodelling stages (positive and negative) which are both associated with plaque physiology and clinical presentation. The different remodelling stages of atherosclerosis are explained with their clinical relevance. Recent advances in basic science have established that atherosclerosis is not only a lipid storage disease, but that also inflammation has a fundamental role in all stages of the disease. The molecular events leading to atherosclerosis will be extensively reviewed and described. Further on in this review different modalities and their role in the different stages of atherosclerosis will be discussed. Non-nuclear invasive imaging techniques (intravascular ultrasound, intravascular MRI, intracoronary angioscopy and intravascular optical coherence tomography) and non-nuclear non-invasive imaging techniques (ultrasound with Doppler flow, electron-bean computed tomography, coronary computed tomography angiography, MRI and coronary artery MR angiography) will be reviewed. After that we focus on nuclear imaging techniques for detecting atherosclerotic plaques, divided into three groups: atherosclerotic lesion components, inflammation and thrombosis. This emerging area of nuclear imaging techniques can provide measures of biological activity of atherosclerotic plaques, thereby improving the prediction of clinical events. As we will see in the future perspectives, at present, there is no special tracer that can be called the diagnostic tool to diagnose prospective stroke or infarction in patients. Nevertheless, we expect such a tracer to be developed in the next few years and maybe, theoretically, it could even be used for targeted therapy (in the form of a beta-emitter) to combat cardiovascular disease.

Citing Articles

An Insight to Nanoliposomes as Smart Radiopharmaceutical Delivery Tools for Imaging Atherosclerotic Plaques: Positron Emission Tomography Applications.

Sebatana R, Kudzai K, Magura A, Mdlophane A, Zeevaart J, Sathekge M Pharmaceutics. 2025; 17(2).

PMID: 40006607 PMC: 11858949. DOI: 10.3390/pharmaceutics17020240.


Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR).

Anzola L, Rivera J, Ramirez J, Signore A, Mut F J Clin Med. 2021; 10(23).

PMID: 34884218 PMC: 8658082. DOI: 10.3390/jcm10235515.


Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.

Dib I, Khalil A, Chouaib R, El-Makhour Y, Noureddine H Mol Biol Rep. 2021; 48(1):875-886.

PMID: 33389539 PMC: 7778846. DOI: 10.1007/s11033-020-06071-5.


Oxidative Stress Biomarkers, Nut-Related Antioxidants, and Cardiovascular Disease.

Dos Santos J, Schaan de Quadros A, Weschenfelder C, Garofallo S, Marcadenti A Nutrients. 2020; 12(3).

PMID: 32138220 PMC: 7146201. DOI: 10.3390/nu12030682.


Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism.

Puca A, Carrizzo A, Spinelli C, Damato A, Ambrosio M, Villa F Eur Heart J. 2019; 41(26):2487-2497.

PMID: 31289820 PMC: 7340354. DOI: 10.1093/eurheartj/ehz459.


References
1.
Dong Z, Chapman S, Brown A, Frenette P, Hynes R, Wagner D . The combined role of P- and E-selectins in atherosclerosis. J Clin Invest. 1998; 102(1):145-52. PMC: 509076. DOI: 10.1172/JCI3001. View

2.
Tearney G, Yabushita H, Houser S, Aretz H, Jang I, Schlendorf K . Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation. 2003; 107(1):113-9. DOI: 10.1161/01.cir.0000044384.41037.43. View

3.
Tsimikas S . Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. Am J Cardiol. 2002; 90(10C):22L-27L. DOI: 10.1016/s0002-9149(02)02958-2. View

4.
Zhao X, Yuan C, Hatsukami T, Frechette E, Kang X, Maravilla K . Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol. 2001; 21(10):1623-9. DOI: 10.1161/hq1001.098463. View

5.
Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View